405 related articles for article (PubMed ID: 17088091)
1. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
Yang WH; Martinot JB; Pohunek P; Beier J; Magula D; Cameron R; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
4. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
[TBL] [Abstract][Full Text] [Related]
7. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
[TBL] [Abstract][Full Text] [Related]
8. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
[TBL] [Abstract][Full Text] [Related]
10. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
Beeh KM; Derom E; Kanniess F; Cameron R; Higgins M; van As A
Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
LaForce C; Alexander M; Deckelmann R; Fabbri LM; Aisanov Z; Cameron R; Owen R; Higgins M
Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
13. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
[TBL] [Abstract][Full Text] [Related]
14. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
Kato M; Makita H; Uemura K; Fukuchi Y; Hosoe M; Emery C; Higgins M; Kramer B
Allergol Int; 2010 Sep; 59(3):285-293. PubMed ID: 20567133
[TBL] [Abstract][Full Text] [Related]
16. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
Barnes PJ; Pocock SJ; Magnussen H; Iqbal A; Kramer B; Higgins M; Lawrence D
Pulm Pharmacol Ther; 2010 Jun; 23(3):165-71. PubMed ID: 20080201
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
Feldman G; Siler T; Prasad N; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
BMC Pulm Med; 2010 Mar; 10():11. PubMed ID: 20211002
[TBL] [Abstract][Full Text] [Related]
18. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
Magnussen H; Verkindre C; Jack D; Jadayel D; Henley M; Woessner R; Higgins M; Kramer B;
Respir Med; 2010 Dec; 104(12):1869-76. PubMed ID: 20850959
[TBL] [Abstract][Full Text] [Related]
20. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
Pearlman DS; Greos L; LaForce C; Orevillo CJ; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
